Let's connect at Bio-Europe in Stockholm.
About us
InCephalo develops exclusively local treatments for neurological diseases, with a focus on cancers in the brain (primary brain cancers as well as secondary brain cancers). The proprietary Compartment Lock technology, also called C-Lock, retains biologics, that are applied locally behind the blood brain barrier, in the central nervous system (CNS) and once they leave the CNS, degrades them rapidly in the systemic compartment. Thereby it significantly improves local CNS therapy, a challenging task with regards to achieving high local concentration (for efficacy) and low systemic footprint (to reduce potential side effects). Especially the peripheral side effects still limit various promising candidates for the treatment of brain cancer or other neurological diseases.
- Website
-
www.incephalo.com
External link for InCephalo
- Industry
- Biotechnology
- Company size
- 2-10 employees
- Type
- Privately Held
- Founded
- 2021
Employees at InCephalo
Updates
-
Exciting time at InCephalo. Join me in welcoming Lorenz Mayr as our new Chair.
-
InCephalo reposted this
Calling all life sciences start-ups! 🚀 Ready to fast-track your success and navigate the regulatory landscape with confidence? Join the DIA Startup Accelerator at #DIAEurope2024 on 12 March in Brussels! This is your chance to get expert guidance directly from regulatory and HTA representatives, demystify the complex world of regulations, and unlock your full potential. Hear firsthand from start-ups like InCephalo who participated in last year's edition. Watch their inspiring journey and learn how DIA Europe helped them pave the way for success. Plus, all participating start-ups receive a complimentary full-day conference pass for DIA Europe. Ready to register? Contact Tereza.krucka@diaglobal.org today! #DIAEurope #StartUp #LifeSciences #Collaboration